Brought to you by 
Myriad Genetics gets rights to Mayo Clinic's Alzheimer's IP
30 Aug 2005
Executive Summary
The Mayo Clinic has granted Myriad Genetics (predictive medicine) the exclusive rights to its newly issued patent that covers the use of selective amyloid beta 42 lowering agents (SALAs) to reduce levels of the peptide.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Myriad Genetics gets rights to Mayo Clinic's Alzheimer's IP
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice